Shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) saw unusually-strong trading volume on Tuesday . Approximately 1,678,202 shares traded hands during trading, an increase of 244% from the previous session’s volume of 488,536 shares.The stock last traded at $1.60 and had previously closed at $1.47.

A number of research firms have recently commented on IDXG. Maxim Group set a $3.00 target price on shares of Interpace Diagnostics Group and gave the stock a “buy” rating in a report on Monday, June 11th. Zacks Investment Research raised shares of Interpace Diagnostics Group from a “hold” rating to a “buy” rating and set a $1.25 target price for the company in a report on Wednesday, August 22nd. HC Wainwright reissued a “buy” rating and issued a $3.00 target price on shares of Interpace Diagnostics Group in a report on Friday, July 20th. ValuEngine raised shares of Interpace Diagnostics Group from a “sell” rating to a “hold” rating in a report on Saturday, June 2nd. Finally, LADENBURG THALM/SH SH began coverage on shares of Interpace Diagnostics Group in a report on Friday, June 22nd. They issued a “buy” rating and a $2.25 target price for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus target price of $2.80.

The firm has a market capitalization of $40.88 million, a P/E ratio of -1.84 and a beta of 2.31.

Interpace Diagnostics Group (NASDAQ:IDXG) last posted its earnings results on Thursday, August 9th. The business services provider reported ($0.07) EPS for the quarter, topping analysts’ consensus estimates of ($0.09) by $0.02. The firm had revenue of $5.50 million during the quarter, compared to analysts’ expectations of $4.80 million. Interpace Diagnostics Group had a negative net margin of 71.14% and a negative return on equity of 34.58%. analysts anticipate that Interpace Diagnostics Group Inc will post -0.34 EPS for the current year.

About Interpace Diagnostics Group (NASDAQ:IDXG)

Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.

Further Reading: How Important is Technical Analysis of Stocks

Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.